Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.

Annals of hematology - 15 May 2026

Ruan Jing, Zhang Yan, Zhou Daobin, Zhang Yan, Zhao Danqing, Wei Chong, Zhang Wei, Li Jian

Abstract excerpt

Although CAR-T cell therapy has emerged as a promising therapeutic option for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), long manufacturing time, high cost and toxicities limit its clinical use. T-cell engagers (TCEs) including glofitamab may address these unmet needs, but real-world data remain scarce. This real-world study (NCT06481826) enrolled 30 Chinese patients. The median prior...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to TP53 gene
Share to Immunotherapy, Adoptive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphocytes

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 42141155
DOI: 10.1007/s00277-026-07068-z
PMCID: PMC13346140

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.PMID 42141155Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in CanadaSemantic proximity Read ↗

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Semantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphomaSemantic proximity Read ↗

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read ↗

Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysisSemantic proximity Read ↗

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Double-Hit Large B Cell Lymphoma.Semantic proximity Read ↗

Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?Semantic proximity Read ↗

Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.